ABSTRACT
Fifty-six patients with Stage III ovarian carcinoma who had a negative second-look laparotomy following optimum cytoreduction, cisplatin, and cyclophosphamide chemotherapy were enrolled in a pilot study to receive consolidation intraperitoneal (IP) chemotherapy. Forty-one patients received three courses of IP cisplatin (80 mg/m2). Fifteen patients with cisplatin-induced toxicity received three courses of IP mitoxantrone (10 mg/m2). Toxicity was minimal, with only 2 patients suffering peritonitis and 1 patient developing an enterotomy at the time of catheter removal. Median follow-up for the IP cisplatin and IP mitoxantrone group has been 24 and 30 months, respectively. Ten of the 41 patients (24%) who received IP cisplatin and 4/15 (26%) of the IP mitoxantrone patients have recurred (P = ns). Median time to recurrence was 18 months for both groups. This study indicates that consolidation intraperitoneal chemotherapy following negative second-look laparotomy is feasible with either cisplatin or mitoxantrone. However, many of these patients still recurred and prospective trials will be required to determine which (if any) consolidation intraperitoneal treatment is best following a negative second-look laparotomy.
Subject(s)
Carcinoma/drug therapy , Cisplatin/therapeutic use , Mitoxantrone/therapeutic use , Neoplasm Recurrence, Local/prevention & control , Ovarian Neoplasms/drug therapy , Carcinoma/surgery , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Cisplatin/adverse effects , Female , Follow-Up Studies , Humans , Infusions, Parenteral , Middle Aged , Mitoxantrone/administration & dosage , Mitoxantrone/adverse effects , Ovarian Neoplasms/surgery , Peritonitis/chemically induced , Pilot Projects , ReoperationABSTRACT
Three cases of papillary villoglandular carcinoma of the cervix are presented. Each patient was multiparous and presented with abnormal vaginal bleeding. The mean age at presentation was 35 years (range 28-42 years). All patients were staged as FIGO IB and underwent radical Wertheim hysterectomy and bilateral pelvic lymphadenectomy. Disease was limited to the cervix in two patients and extended to involve the lower uterine segment in one patient. There was no evidence of microscopic spread to the lymph nodes. Previous reports that examined patients with papillary villoglandular carcinoma of the cervix found them to have a favorable prognosis. Treatment implications are discussed.
Subject(s)
Carcinoma, Papillary/diagnosis , Uterine Cervical Neoplasms/diagnosis , Adult , Carcinoma, Papillary/pathology , Carcinoma, Papillary/surgery , Female , Humans , Prognosis , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgeryABSTRACT
Efficacy of oral medroxyprogesterone acetate (MPA) was assessed in 35 women with an established diagnosis of endometriosis (33 pelvic and 2 abdominal). MPA was given in a dosage of 30 mg daily for 90 days. Results indicated improvement or remission in all cases, even though breakthrough bleeding occurred in 8. Twenty-six were treated for associated infertility. Twelve of these became pregnant following treatment. Pregnancy rate in those women whose husbands were fertile was 90%. Side effects included spotting and breakthrough bleeding. The patients usually remained amenorrheic and anovulatory while receiving MPA. Posttreatment resumption of ovulation was prompt. The findings indicate that oral MPA is a useful therapeutic agent in the management of minimal to moderate endometriosis, particularly when it is associated with infertility.
Subject(s)
Abdominal Neoplasms/drug therapy , Endometriosis/drug therapy , Medroxyprogesterone/therapeutic use , Pelvic Neoplasms/drug therapy , Administration, Oral , Female , Humans , Male , Medroxyprogesterone/administration & dosage , Medroxyprogesterone/adverse effects , Pregnancy , Progesterone/bloodSubject(s)
Adenocarcinoma/surgery , Carcinoma in Situ/surgery , Carcinoma, Basal Cell/surgery , Carcinoma, Squamous Cell/surgery , Melanoma/surgery , Paget Disease, Extramammary/surgery , Vulvar Neoplasms/surgery , Adenocarcinoma/pathology , Adult , Aged , Carcinoma in Situ/pathology , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Melanoma/pathology , Methods , Middle Aged , Neoplasm Recurrence, Local , Paget Disease, Extramammary/pathology , Postoperative Complications , Prospective Studies , Vulvar Neoplasms/mortality , Vulvar Neoplasms/pathology , Vulvar Neoplasms/radiotherapySubject(s)
Leiomyoma , Pregnancy Complications , Uterine Neoplasms , Adult , Castration , Female , Humans , Hysterectomy , Leiomyoma/pathology , Leiomyoma/surgery , Lung Neoplasms/diagnostic imaging , Lymph Nodes/pathology , Lymphatic Metastasis , Neoplasm Metastasis , Pregnancy , Radiography , Retroperitoneal Neoplasms/pathology , Retroperitoneal Neoplasms/surgery , Uterine Neoplasms/pathology , Uterine Neoplasms/surgeryABSTRACT
In a double-blind cross-over trial the effects of nitrazepam (5 and 10 mg.), amylobarbitone sodium (100 and 200 mg.), and placebo were compared in normal healthy young people. Though they reported a good night's sleep and adjudged themselves to be alert after all four drug treatments, behavioural tests showed their performance to be significantly impaired 13 hours after treatment with nitrazepam or amylobarbitone, and E.E.G. records showed more drowsiness and light sleep 18 hours after treatment with nitrazepam than with amylobarbitone or placebo. E.E.G. fast activity was more plentiful after drugs in either dosage than with placebo.